Breast cancer is hormone-dependent; endocrine therapy in patients with estrogen receptor (ER) and progesterone receptor (PR) positive breast malignancies can reduce the risk for breast cancer recurrence and metastasis [1]. Here, ESR1 is linked to breast carcinoma.